Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
复制标题
DOI:
10.1126/scitranslmed.aah6144
复制
发表时间:
2017-06-14
影响因子:
17.1
通讯作者:
Sos ML
中科院分区:
文献类型:
--
作者:
Plenker D;Riedel M;Brägelmann J;Dammert MA;Chauhan R;Knowles PP;Lorenz C;Keul M;Bührmann M;Pagel O;Tischler V;Scheel AH;Schütte D;Song Y;Stark J;Mrugalla F;Alber Y;Richters A;Engel J;Leenders F;Heuckmann JM;Wolf J;Diebold J;Pall G;Peifer M;Aerts M;Gevaert K;Zahedi RP;Buettner R;Shokat KM;McDonald NQ;Kast SM;Gautschi O;Thomas RK;Sos ML
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. Here, we provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors such as AD80 or ponatinib that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in RET-rearranged cells we identify the CCDC6-RETI788N mutation and drug-induced MAPK pathway reactivation as possible mechanisms, by which tumors may escape the activity of RET inhibitors. Our data provide mechanistic insight into the druggability of RET kinase fusions that may be of help for the development of effective therapies targeting such tumors.
登录
查看更多内容
影响因子:
28.2
作者:
Drilon A;Wang L;Hasanovic A;Suehara Y;Lipson D;Stephens P;Ross J;Miller V;Ginsberg M;Zakowski MF;Kris MG;Ladanyi M;Rizvi N
通讯作者:
Rizvi N
影响因子:
7.3
作者:
Hasegawa, Masaichi;Nishigaki, Naohiko;Cheung, Mui
通讯作者:
Cheung, Mui
影响因子:
64.5
作者:
Azam, M;Latek, RR;Daley, GQ
通讯作者:
Daley, GQ
影响因子:
7.3
作者:
Engel, Julian;Richters, Andre;Rauh, Daniel
通讯作者:
Rauh, Daniel
影响因子:
4.4
作者:
JORGENSEN, WL;CHANDRASEKHAR, J;KLEIN, ML
通讯作者:
KLEIN, ML